MDxHealth reports preliminary Q2 revenue $22.2M, consensus $20.21M

The Company expects to report Q2 and half year 2024 revenues of approximately $22.2 and $42.0 million, respectively, representing year-over-year growth of 32% and 34%, respectively, and representing sequential growth from Q1 of 12%. The Company is raising its full-year 2024 revenue guidance from $83-85 million to $85-87 million. Michael McGarrity, CEO of mdxhealth, commented: “We believe these preliminary results for mdxhealth reflect our stated and firm commitment to deliver consistent and sustainable growth in our business, driven by our broad menu, sales execution and operating discipline. We are quite confident that this execution is now fundamentally built in across our operating teams and provide a unique profile of top line growth trajectory and operating leverage to meet our expected turn to adjusted EBITDA profitability in the first half of 2025.